TRK fusions
Jump to navigation
Jump to search
TRK fusions are seen in many solid tumours of children and adults and have targeted drugs.[1]
General
Genes
- TRK1.
- TRK2.
- TRK3.
Notes:
- The TRK genes are tropomyosine kinase receptors.
- Multiple fusion partners for each gene.
- Testing: RNA-based next generation sequencing or immunohistochemistry (limited sensitivity).[2]
Classic associations
- Mammary analogue secretory carcinoma (MASC) - ETV6-NTRK3.[3]
- Secretory breast carcinoma - ETV6-NTRK3.[4]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Drilon, A.; Laetsch, TW.; Kummar, S.; DuBois, SG.; Lassen, UN.; Demetri, GD.; Nathenson, M.; Doebele, RC. et al. (02 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.". N Engl J Med 378 (8): 731-739. doi:10.1056/NEJMoa1714448. PMID 29466156.
- ↑ Hechtman, JF.; Benayed, R.; Hyman, DM.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, ME.; Dogan, S. et al. (Nov 2017). "Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.". Am J Surg Pathol 41 (11): 1547-1551. doi:10.1097/PAS.0000000000000911. PMID 28719467.
- ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.